Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 3961 AL 3975

Alzheimer's Disease: Characterization of the Brain Sites of the Initial Tau Cytoskeletal Pathology Will Improve the Success of Novel Immunological Anti-Tau Treatment Approaches

Rüb U, Stratmann K, Heinsen H, Seidel K, Bouzrou M, Korf HW.

J Alzheimers Dis. 2017;57(3):683-696. doi: 10.3233/JAD-161102.

Tacrine-based Multifunctional Agents in Alzheimer's Disease: An Old Story in Continuous Development§

Milelli A, De Simone A, Ticchi N, Chen HH, Betari N, Andrisano V, Tumiatti V.

Curr Med Chem. 2017;24(32):3522-3546. doi: 10.2174/0929867324666170309123920.

Mechanisms of Melatonin in Alleviating Alzheimer's Disease

Shukla M, Govitrapong P, Boontem P, Reiter RJ, Satayavivad J.

Curr Neuropharmacol. 2017;15(7):1010-1031. doi: 10.2174/1570159X15666170313123454.

Systemic and network functions of the microtubule-associated protein tau: Implications for tau-based therapies

Bakota L, Ussif A, Jeserich G, Brandt R.

Mol Cell Neurosci. 2017 Oct;84:132-141. doi: 10.1016/j.mcn.2017.03.003. Epub 2017 Mar 17.

Direct and indirect cost of managing alzheimer's disease and related dementias in the United States

Deb A, Thornton JD, Sambamoorthi U, Innes K.

Expert Rev Pharmacoecon Outcomes Res. 2017 Apr;17(2):189-202. doi: 10.1080/14737167.2017.1313118.

Nanotechnological strategies for nerve growth factor delivery: Therapeutic implications in Alzheimer's disease

Faustino C, Rijo P, Reis CP.

Pharmacol Res. 2017 Jun;120:68-87. doi: 10.1016/j.phrs.2017.03.020. Epub 2017 Mar 27.

Is VEGF a Key Target of Cotinine and Other Potential Therapies Against Alzheimer Disease?

Echeverria V, Barreto GE, Avila-Rodriguezc M, Tarasov VV, Aliev G.

Curr Alzheimer Res. 2017;14(11):1155-1163. doi: 10.2174/1567205014666170329113007.

Preclinical to phase II amyloid beta (A(β)) peptide modulators under investigation for Alzheimer's disease

Parsons CG, Rammes G.

Expert Opin Investig Drugs. 2017 May;26(5):579-592. doi: 10.1080/13543784.2017.1313832.

Contextualized Autonomy and Liberalism: Broadening the Lenses on Complementary and Alternative Medicines in Preclinical Alzheimer's Disease

Racine E, Aspler J, Forlini C, Chandler JA.

Kennedy Inst Ethics J. 2017;27(1):1-41. doi: 10.1353/ken.2017.0002.

Recent progress in the identification of selective butyrylcholinesterase inhibitors for Alzheimer's disease

Li Q, Yang H, Chen Y, Sun H.

Eur J Med Chem. 2017 May 26;132:294-309. doi: 10.1016/j.ejmech.2017.03.062. Epub 2017 Mar 27.

Cognitive Rehabilitation in Alzheimer's Disease: A Controlled Intervention Trial

Brueggen K, Kasper E, Ochmann S, Pfaff H, Webel S, Schneider W, Teipel S.

J Alzheimers Dis. 2017;57(4):1315-1324. doi: 10.3233/JAD-160771.

Alzheimer's disease: where next for anti-amyloid therapies?

Hardy J, De Strooper B.

Brain. 2017 Apr 1;140(4):853-855. doi: 10.1093/brain/awx059.

Bapineuzumab for mild to moderate Alzheimer's disease: a meta-analysis of randomized controlled trials

Abushouk AI, Elmaraezy A, Aglan A, Salama R, Fouda S, Fouda R, AlSafadi AM.

BMC Neurol. 2017 Apr 4;17(1):66. doi: 10.1186/s12883-017-0850-1.

EFAD transgenic mice as a human APOE relevant preclinical model of Alzheimer's disease

Tai LM, Balu D, Avila-Munoz E, Abdullah L, Thomas R, Collins N, Valencia-Olvera AC, LaDu MJ.

J Lipid Res. 2017 Sep;58(9):1733-1755. doi: 10.1194/jlr.R076315. Epub 2017 Apr 7.

Editorial (Thematic Issue: Hybrid Compounds as Multitarget Agents in Medicinal Chemistry - Part II)

Scotti L, Mendonça-Junior FJ, Scotti MT.

Curr Top Med Chem. 2017;17(9):957-958. doi: 10.2174/156802661709170213205211.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias